Healthcare Reform

Trend towards HTA collaboration boosts need for data

The rising popularity of health technology assessments (HTAs) and similar framework agreements is presenting new challenges for the pharmaceutical industry.…

Germany’s ESG Law: A case study for new pharma pricing model

Pharmaceutical pricing is increasingly becoming a broader topic in the global push towards sustainability and environmental, social, and government (ESG)…

AMNOG ten years on: Impact on the Europe top 5 price level hierarchy

Ten years after implementation of the AMNOG reform in Germany, the price level hierarchy among the Europe Top 5 markets…

US drug prices rise over 4% in 2021 reversing multi-year trend of slowed growth

Usually in January, every year, a large number of pharmaceutical companies update product prices - a trend that often receives…

Pharma and healthcare top 10: What to expect in 2021 and beyond

After the extreme unpredictability of 2020, the world is now looking at 2021 with the hope to return to a…

Risks to UK pharmaceutical spending from a US-UK free trade deal

A leaked document about UK-US free trade deal discussions back in 2017 has dominated UK media coverage over the past…

Germany’s fixed pricing for medicines faces European reckoning

Fixed prices for prescription medicines are an important part of the framework of pharmaceutical pricing and reimbursement regulation in Germany.…

Ten-year Medicare budget impact of increased coverage for anti-obesity intervention

Obesity rates have reached 37.5% and 39.4% among men and women age 60 and older by 2014, respectively, compared to…

South Korean pharma dreams struggle

In September, South Korean drugmaker Hanmi Pharmaceutical signed a collaboration agreement with US biotech Phanes Therapeutics focusing on dual- and…

Taking the pulse of international reference pricing

What a difference a year (or two) makes. When we published the 2017 edition of our International Reference Pricing Guidebook,…